TRIL - Trillium Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.2650
+0.4950 (+17.87%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.7700
Open2.9700
Bid2.9100 x 1200
Ask2.9500 x 1800
Day's Range2.9500 - 3.8900
52 Week Range0.2410 - 3.9000
Volume16,893,216
Avg. Volume2,935,958
Market Cap90.434M
Beta (5Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-2.5480
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.02
  • GlobeNewswire

    Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

    Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of common shares (the “Common Shares”) of the Company and Series II Non-Voting Convertible First Preferred Shares (the “Series II First Preferred Shares”) of the Company (the “Offering”). In addition, Trillium intends to grant the underwriters a 30-day option to purchase up to an additional amount of Common Shares equal to 15% of the Common Shares and Series II First Preferred Shares offered in the Offering.

  • GlobeNewswire

    Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

    Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the Company has regained compliance with the Nasdaq Capital Market minimum bid price requirement, and the matter is now closed. According to the letter received from the Nasdaq Listing Qualifications Department, the closing bid price of the Company’s common stock has been at $1.00 per share or greater for a minimum of 10 consecutive days, and the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer.

  • MarketWatch

    Trillium Therapeutics' stock rockets on heavy volume after an upbeat update on cancer-treatment programs

    Shares of Trillium Therapeutics Inc. nearly doubled in very active trading Thursday, after the developer of cancer treatments provided an upbeat update on its TTI-621 and TTI-622 programs. The stock shot up 93% in afternoon trading, toward the highest close since Nov. 30. Trading volume spiked to 46.4 million shares, well above the full-day average of about 2.3 million shares. The company said it has completed the initial-dose-finding and signal-seeking parts of a phase 1 study of intravenous TTI-621, and the program continues to demonstrate "clear single agent activity across a range of hematologic malignancies, as well as a strong tolerability profile, Chief Executive Jan Skvarka stated. "We are equally excited about the dose escalation progress with our IgG4-based agent, TTI-622," Chief Medical Officer Yaping Shou said. The stock has run up nearly 10-fold (up 880%) over the past three months, while the S&P 500 has climbed 12.1%.

  • GlobeNewswire

    Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

    Intravenous TTI-621 dose escalation under initial dose limiting toxicity (DLT) criteria now completed – confirms TTI-621 monotherapy activity (including complete responses) in.

  • Is the Options Market Predicting a Spike in Trillium (TRIL) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Trillium (TRIL) Stock?

    Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

  • Trillium Therapeutics Inc. (NASDAQ:TRIL): Are Hedge Funds Right About This Stock?
    Insider Monkey

    Trillium Therapeutics Inc. (NASDAQ:TRIL): Are Hedge Funds Right About This Stock?

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industries and media insiders on top of […]

  • GlobeNewswire

    Trillium Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September 30, 2019, and provided a corporate update.

  • Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y
    Zacks

    Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

    Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.

  • Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales
    Zacks

    Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales

    Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.

  • GlobeNewswire

    Trillium Therapeutics to Report Preclinical Data on Its STING Program at the SITC 34th Annual Meeting

    TORONTO, Nov. 06, 2019 -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,.

  • GlobeNewswire

    Trillium Therapeutics Announces Corporate Restructuring and Provides CD47 Program Update

    Trillium Therapeutics Inc. (Trillium, "the company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced corporate restructuring to extend the company’s cash runway and to focus on critical value-creating activities. The company also provided an update on its clinical development and research programs. “Since assuming the CEO role a month ago, my immediate focus has been on conducting an in-depth review of our strategic priorities and ongoing programs, as well as our available resources,” said Jan Skvarka, President and Chief Executive Officer of the company.

  • GlobeNewswire

    Trillium Granted 180-Day Extension by NASDAQ to Regain Compliance With Minimum Bid Price Rule

    Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is eligible for an additional 180 calendar day period to regain compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market (the “Exchange”). The notification has no immediate effect on the listing of the Company’s common shares on the Exchange.

  • GlobeNewswire

    Trillium Therapeutics Appoints Jan Skvarka as President and Chief Executive Officer

    Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of Mr. Jan Skvarka as President and Chief Executive Officer effective today. Mr. Skvarka has also been appointed to the Board of Directors of the company. “We are looking forward to his leadership as we continue to advance the clinical development of TTI-621, our novel CD47 immune checkpoint inhibitor.

  • GlobeNewswire

    Trillium Therapeutics Reports Second Quarter 2019 Financial Results

    TORONTO, Aug. 13, 2019 -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,.

  • GlobeNewswire

    Trillium Therapeutics Provides Corporate Update

    Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update. “Trillium continues to make progress with both our intratumoral and intravenous development programs for TTI-621, our novel CD47 immune checkpoint inhibitor,” said Robert L. Kirkman, M.D., Executive Chair of Trillium.

  • GlobeNewswire

    Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

    TORONTO, July 02, 2019 -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,.

  • Associated Press

    Trillium: 1Q Earnings Snapshot

    On a per-share basis, the Mississauga, Ontario-based company said it had a loss of 46 cents. The company's shares closed at 59 cents. A year ago, they were trading at $6.60. _____ This story was generated ...

  • GlobeNewswire

    Trillium Therapeutics Reports First Quarter 2019 Financial Results

    TORONTO, May 13, 2019 -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,.

  • GlobeNewswire

    Trillium Announces Management and Board Changes and Provides Corporate Update

    Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announces changes to its executive management team, its board of directors and provides an operational update. Niclas Stiernholm, Ph.D., has informed the Board of Directors of his resignation as President & Chief Executive Officer of the Company effective April 29, 2019.  In addition, Dr. Stiernholm has resigned as a director of the Company.

  • GlobeNewswire

    Trillium Therapeutics Announces Publication Highlighting Activity of TTI-621 in Sézary Syndrome Patients

    TORONTO, April 15, 2019 -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer,.

  • GlobeNewswire

    Trillium Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

    Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

  • GlobeNewswire

    Trillium Therapeutics to Present at Investor Conferences in April

    TORONTO, April 08, 2019 -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,.

  • GlobeNewswire

    Trillium Therapeutics Expands Immuno-Oncology Pipeline With STING Agonist Program

    Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has expanded its immuno-oncology pipeline with a STING agonist program and presented preclinical data from this program at the 2019 Annual Meeting of the American Association for Cancer Research (AACR). STING (stimulator of interferon genes) is an adaptor protein involved in sensing cytosolic DNA that plays a key role in promoting tumor immunity.

  • GlobeNewswire

    Trillium Therapeutics to Unveil its STING Agonist Program at the AACR Annual Meeting 2019

    TORONTO, March 27, 2019 -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer,.

  • ACCESSWIRE

    Four Healthcare Stocks Picking Up Speed on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 27, 2019 / The future of the healthcare stock market is directly correlated to whether companies in the healthcare sector have what it takes to meet the growing health challenges facing society. According to recent statistics, global shortages in primary care physicians coupled with rising populations has left millions without access to acute care. Luckily, there are healthcare companies rising to the challenge with innovative medical technologies and nuanced approaches to how we treat and care for our patients.